Compare Docusign Inc (DOCU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Docusign Inc trades at $51.16 (market cap $9.43B), while State Street SPDR S&P Biotech ETF trades at $156.15. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Docusign Inc nearer its low. Which is the better fit depends on your goals.
| DOCU | XBI | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $85.01 | $164.28 |
52-Week Low | $41.75 | $85.16 |
Enterprise Value | $8.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $49.87, up 1.4% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growth to $2.98B in 2025 and net income of $1.07B, supported by consistent earnings beats. Recent partnerships with Perplexity and Slack highlight innovation in agreement management, while analyst sentiment remains mixed with a $55.40 consensus target.
Outlook is cautiously optimistic given solid profitability and strategic initiatives, but risks include pricing pressure and sector volatility. The stock presents a growth opportunity if execution continues, though investor patience is required amid competitive and macroeconomic headwinds.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
